FDA grants St. Jude approval for Trifecta valve

Kaitlyn Dmyterko | | Health Imaging | Screening
The FDA has granted St. Jude Medical approval for its Trifecta valve, a pericardial aortic tissue valve used in the replacement of diseased, damaged or malfunctioning aortic heart valves.

St. Paul, Minn.-based St. Jude said that the Trifecta valve optimizes blood flow and produces long-term durability and is constructed using a polyester and tissue-covered titanium stent.

The valve also has leaflets from pericardial tissue that are attached to the exterior of the valve’s stent, which mimic a healthy aortic heart valve and limit tissue abrasion through stent-to-leaflet contact.

St. Jude said that the device makes implantation easier and gives physicians more control. The valve was approved for use in Europe and Canada in 2010.

Kaitlyn Dmyterko

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.